Клиническое исследование

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT: NCT06831136 · RECRUITING

NCT IDNCT06831136

СтатусRECRUITING

Дата начала2025-03-26

Завершение2030-01-20

SponsorThe University of Texas Health Science Center, Houston (OTHER)

First posted2025-02-17

Last updated2026-10-08

Краткое описание

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

Официальный источник

Открыть на ClinicalTrials.gov →

Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.